Buy Rating for Kura Oncology Supported by Promising Ziftomenib Data and Strategic Drug Development
In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report), with ...
Le Lézard1d
Lomond Therapeutics Completes Reverse Merger and Closes $44 Million Private Placement
Lomond Therapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological ...